Aurinia Pharmaceuticals Inc is a biotechnology business based in the US. Aurinia Pharmaceuticals shares (AUPH) are listed on the NASDAQ and all prices are listed in US Dollars. Aurinia Pharmaceuticals employs 294 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $16.26 |
|---|---|
| 52-week range | $9.72 - $33.97 |
| 50-day moving average | $21.81 |
| 200-day moving average | $17.69 |
| Wall St. target price | $31.56 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.22 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $16.26 from 2022-01-25
| 1 week (2022-01-19) | -12.30% |
|---|---|
| 1 month (2021-12-23) | -29.46% |
| 3 months (2021-10-26) | -46.43% |
| 6 months (2021-07-26) | 48.76% |
| 1 year (2021-01-26) | -7.72% |
|---|---|
| 2 years (2020-01-24) | -14.20% |
| 3 years (2019-01-25) | 165.25% |
| 5 years (2017-01-26) | 433.11% |
| Revenue TTM | $72.2 million |
|---|---|
| Gross profit TTM | $-209,000 |
| Return on assets TTM | -23.99% |
| Return on equity TTM | -44.01% |
| Profit margin | -215.58% |
| Book value | $2.30 |
| Market capitalisation | $2.1 billion |
TTM: trailing 12 months
We're not expecting Aurinia Pharmaceuticals to pay a dividend over the next 12 months.
Aurinia Pharmaceuticals's shares were split on a 1:50 basis on 22 October 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aurinia Pharmaceuticals shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Aurinia Pharmaceuticals shares which in turn could have impacted Aurinia Pharmaceuticals's share price.
Over the last 12 months, Aurinia Pharmaceuticals's shares have ranged in value from as little as $9.72 up to $33.972. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aurinia Pharmaceuticals's is 0.6898. This would suggest that Aurinia Pharmaceuticals's shares are less volatile than average (for this exchange).
Aurinia Pharmaceuticals Inc. , a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. , Ltd. The company is headquartered in Victoria, Canada. .
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
